• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $LVTX

    LAVA Therapeutics N.V.

    Subscribe to $LVTX
    $LVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates. The company was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

    IPO Year: 2021

    Exchange: NASDAQ

    Website: lavatherapeutics.com

    Recent Analyst Ratings for LAVA Therapeutics N.V.

    DatePrice TargetRatingAnalyst
    12/12/2024$11.00 → $2.00Outperform → Market Perform
    Leerink Partners
    12/11/2024Mkt Outperform → Mkt Perform
    JMP Securities
    10/25/2022$9.00Buy
    H.C. Wainwright
    11/16/2021$24.00 → $20.00Outperform
    SVB Leerink
    8/17/2021$26.00 → $24.00Outperform
    SVB Leerink
    See more ratings

    LAVA Therapeutics N.V. Financials

    Live finance-specific insights

    See more
    • LAVA Therapeutics to Present Initial Phase 1/2a Clinical Trial Dose Escalation Data of LAVA-051 in Chronic Lymphocytic Leukemia and Multiple Myeloma Patients at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

      UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the presentation of initial dose-escalation data from the Phase 1/2a clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago and virtually June 3-7, 2022. "These dose-escalation data from the first four cohorts of our Phase 1/2a clinical tria

      6/1/22 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    LAVA Therapeutics N.V. SEC Filings

    See more
    • SEC Form DEF 14A filed by LAVA Therapeutics N.V.

      DEF 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/28/25 4:08:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form PRE 14A filed by LAVA Therapeutics N.V.

      PRE 14A - LAVA Therapeutics NV (0001840748) (Filer)

      4/15/25 4:23:35 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by LAVA Therapeutics N.V.

      S-8 - LAVA Therapeutics NV (0001840748) (Filer)

      3/28/25 4:47:54 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by LAVA Therapeutics N.V.

      10-K - LAVA Therapeutics NV (0001840748) (Filer)

      3/28/25 4:06:33 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics N.V. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - LAVA Therapeutics NV (0001840748) (Filer)

      3/28/25 7:35:03 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by LAVA Therapeutics N.V.

      SCHEDULE 13G - LAVA Therapeutics NV (0001840748) (Subject)

      3/3/25 2:03:50 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by LAVA Therapeutics N.V.

      8-K - LAVA Therapeutics NV (0001840748) (Filer)

      2/28/25 4:05:27 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics N.V. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Regulation FD Disclosure

      8-K - LAVA Therapeutics NV (0001840748) (Filer)

      2/25/25 7:12:12 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics N.V. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - LAVA Therapeutics NV (0001840748) (Filer)

      1/2/25 8:45:12 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by LAVA Therapeutics N.V.

      6-K - LAVA Therapeutics NV (0001840748) (Filer)

      12/10/24 4:05:15 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    LAVA Therapeutics N.V. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • LAVA Therapeutics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded LAVA Therapeutics from Outperform to Market Perform and set a new price target of $2.00 from $11.00 previously

      12/12/24 8:11:38 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics downgraded by JMP Securities

      JMP Securities downgraded LAVA Therapeutics from Mkt Outperform to Mkt Perform

      12/11/24 7:55:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on LAVA Therapeutics with a new price target

      H.C. Wainwright initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $9.00

      10/25/22 6:28:17 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on LAVA Therapeutics with a new price target

      SVB Leerink reiterated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $20.00 from $24.00 previously

      11/16/21 9:12:29 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on LAVA Therapeutics with a new price target

      SVB Leerink reiterated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $24.00 from $26.00 previously

      8/17/21 6:28:34 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JP Morgan initiated coverage on LAVA Therapeutics with a new price target

      JP Morgan initiated coverage of LAVA Therapeutics with a rating of Overweight and set a new price target of $22.00

      4/19/21 7:46:27 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on LAVA Therapeutics with a new price target

      Jefferies initiated coverage of LAVA Therapeutics with a rating of Buy and set a new price target of $23.00

      4/19/21 7:46:05 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink initiated coverage on LAVA Therapeutics with a new price target

      SVB Leerink initiated coverage of LAVA Therapeutics with a rating of Outperform and set a new price target of $26.00

      4/19/21 7:00:15 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    LAVA Therapeutics N.V. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • LAVA Therapeutics Granted Full Waiver for RVO Payment Obligation

      Exemption from the $5.1 million repayment obligation strengthens LAVA's balance sheet Underscores focus on cost curtailment and strategic option evaluation UTRECHT, The Netherlands and PHILADELPHIA, April 16, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that the Netherlands Enterprise Agency (Rijksdienst voor Ondernemend Nederland, RVO) granted a full waiver of the final payment obligation related to the Innovation Credit, in the amount of $5.1 million. "As part of LAVA's ongoing strategic

      4/16/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

      Focused on the evaluation of strategic alternativesAdopted a restructuring plan to extend capital resources, incurring a reduction in workforce of 30% to support the evaluation of strategic options and the Phase 1 study for LAVA-1266Phase 1 enrollment in LAVA-1266 clinical trial underwayJohnson and Johnson development milestone of $5.0 million achieved and received in Q4 2024Cash balance of $76.6 million as of December 31, 2024 expected to fund operations into 2027 UTRECHT, The Netherlands and PHILADELPHIA, March 28, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammab

      3/28/25 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Announces Evaluation of Strategic Options

      Advisor engaged in evaluating strategic options to maximize shareholder value Cash balance of $76.6 million as of December 31, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced that the Company has initiated a process to review strategic options focused on maximizing shareholder value and has implemented cost curtailment including a workforce reduction. The Company has retained an experienced financial advisor to

      2/25/25 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers

      LAVA-1266 is a potent and selective bispecific anti-CD123 Gammabody®First-in-human study enrolling adult patients with CD123-expressing AML or MDSInitial Phase 1 data read-out expected by year-end 2025 UTRECHT, The Netherlands and PHILADELPHIA, Jan. 10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted Gammabody®, LAVA-1266, an investigational agent in development for the treatment of hematologic cancers including a

      1/10/25 8:23:53 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027

      Reprioritized pipeline to focus on LAVA-1266, with continued support for partnered programs with Pfizer (PF-08046052) and Johnson and Johnson (JNJ-89853413) and plan to discontinue development of LAVA-1207Fourth quarter pipeline advances include initiation of the Phase 1 trial for LAVA-1266, for hematologic malignancies, and a $5.0 million milestone payment from Johnson and JohnsonCash runway extended into 2027, based on a cash balance of $78.9 million, as of September 30, 2024 UTRECHT, The Netherlands and PHILADELPHIA, Dec. 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company")), a clinical-stage immuno-oncology company focused on developing its proprie

      12/10/24 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

      UTRECHT, The Netherlands and PHILADELPHIA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 26th Annual Global Investment Conference. Presentation DetailsFormat: Fireside ChatDate: Monday, September 9, 2024Time: 3:30 PM ET A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavatherapeutics.com/news

      9/3/24 8:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Reports Second Quarter 2024 Financial Results and Business Update

      Continued progress in Phase 1/2a dose escalation for LAVA-1207, including the monotherapy arm, now enrolling in dose level 12, and the pembrolizumab combinationFavorable safety profile for LAVA-1207Next data update for LAVA-1207 program expected in Q4 2024Strong balance sheet with cash of $86.8 million supports runway into mid-2026 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " "the Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced financial results for the second quarter ended June 3

      8/20/24 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference

      UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference. Presentation Details Format: Fireside Chat Date: Tuesday, June 25, 2024Time: 9:30 AM ET A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at https://ir.lavather

      6/20/24 7:30:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Announces Annual Meeting of Shareholders

      UTRECHT, The Netherlands and PHILADELPHIA, June 10, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced the annual general meeting of shareholders will take place on Wednesday, June 19, 2024 at 2:00 pm CEST. All relevant documents and information relating to the annual general meeting, including the notice and agenda for the annual general meeting, are available in the "Investors" section of LAVA's website (www.lavatherapeutics.com) under "Annual Meeting." The documents will also be made available on the SEC's we

      6/10/24 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference

      UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX, "LAVA, " or "Company"))), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma-delta (δ2) T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will participate in a fireside chat at the Jefferies Global Healthcare Conference. Presentation Details Format: Fireside ChatDate: Wednesday, June 5, 2024Time: 8:00 a.m. ET A webcast of the fireside chat can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at h

      5/30/24 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    LAVA Therapeutics N.V. Leadership Updates

    Live Leadership Updates

    See more

    LAVA Therapeutics N.V. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    LAVA Therapeutics N.V. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of Directors

      UTRECHT, The Netherlands and PHILADELPHIA, March 09, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced the appointment of Christy J. Oliger to its board of directors effective March 9, 2023. Ms. Oliger brings extensive commercial, portfolio management, and senior leadership experience to the role. Additionally, Stefan Luzi, Ph.D., will step down from his role on the LAVA Board. "As an accomplished leader in the pharmaceutical and biotechnology industry with deep experience in oncology, Ms. Oliger brings over three deca

      3/9/23 8:05:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical Officer

      UTRECT, The Netherlands and PHILADELPHIA, Feb. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Dr. Charles Morris has joined LAVA as chief medical officer effective February 6, 2023. Dr. Morris will replace Benjamin Winograd, MD, PhD. "During a 25-year tenure in the industry, Dr. Morris has demonstrated a proven track record of advancing novel oncology product candidates from clinical development through global regulatory approvals," said Stephen Hurly, president and chief executive offi

      2/6/23 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

      LAVA-051 updated interim data from ongoing Phase 1/2a clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia and multiple myeloma to be presented at 2022 American Society of Hematology (ASH) Annual MeetingPresented LAVA-051 clinical pharmacodynamic data demonstrating consistency with mechanism of action data at the Society for Immunotherapy for Cancer (SITC) 2022 Annual MeetingAnnounced exclusive worldwide license agreement with Seagen to advance LAVA-1223, a preclinical bispecific gamma delta T cell engager for EGFR-expressing solid tumorsCash and investments of $92.7 million as of September 30, 2022, plus$50.0 million received from Seagen in October provide cas

      11/16/22 4:05:00 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

      UTRECHT, The Netherlands and PHILADELPHIA, Nov. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers, today announced the appointment of Fred M. Powell as Chief Financial Officer, effective today. Mr. Powell brings over 20 years of global CFO experience in the biopharmaceutical industry, including investor relations, administration, operations and information technology. "I am pleased to welcome Fred to LAVA's executive team. He brings extensive expertise in financial leadership and is a seasoned executive having served as a CFO for sev

      11/1/22 7:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Forbion Appoints Nanna Lüneborg as a General Partner

      Forbion Appoints Nanna Lüneborg as a General Partner - Brings extensive international investment and board experience in life sciences companies of all sizes including company creations, private venture deals and IPOs - Naarden, The Netherlands, 1 September 2021 – Forbion, a leading European life sciences venture capital firm, today announces the appointment of Nanna Lüneborg, PhD as a General Partner to work on the €360m Forbion Growth Opportunities Fund. Prior to joining Forbion, Nanna was a Partner at Novo Ventures and a key member of the European deal team focussing on late-stage biopharma investments across Europe. During her 10 years at Novo, Nanna was involved in numerous success

      9/1/21 3:00:00 AM ET
      $IVA
      $LVTX
      $OBSV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Provides Business Update and Reports Second Quarter Results

      Enrollment continues in Phase 1/2a trial evaluating LAVA-051 in hematological malignancies CTA accepted and IND cleared for Phase 1/2a trial evaluating LAVA-1207 in metastatic castrate resistant prostate cancer; on track to begin later this year Collaboration with Janssen Biotech, Inc. remains on track and progressing towards potential milestones Cash balance of $151 million expected to fund operations into the second half of 2023 UTRECHT, The Netherlands and PHILADELPHIA, Aug. 16, 2021 (GLOBE NEWSWIRE) --  LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers (bsTCEs) to transform the t

      8/16/21 7:05:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary

      UTRECHT, The Netherlands and PHILADELPHIA, July 27, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ:LVTX), a clinical-stage biotechnology company focused on developing bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced the appointment of Amy Garabedian as general counsel and corporate secretary. Ms. Garabedian is a seasoned leader with extensive corporate and transactional expertise within the life science industry. "We are very pleased to welcome Amy to our executive team. Amy's proven experience across a wide range of complex strategic legal and corporate matters in life sciences will be invaluable as our differentiated pipeline of bis

      7/27/21 8:00:00 AM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Cooperatieve Gilde Healthcare Iv U.A. claimed ownership of 5,421,170 shares (SEC Form 3)

      3 - LAVA Therapeutics NV (0001840748) (Issuer)

      4/8/25 6:19:03 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wilson Karen J

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:24 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Backstrom Jay T.

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:15 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Kiener Peter A

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:17 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Noble James

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:20 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wadlinger Mary E.

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:22 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Powell Fred M

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:11 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Dhingra Kapil

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:13 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Morris Charles Q

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:09 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Oliger Christy J.

      4 - LAVA Therapeutics NV (0001840748) (Issuer)

      2/18/25 8:15:07 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      3/7/24 7:09:56 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

      2/14/24 4:26:22 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      11/9/23 4:37:57 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      6/5/23 8:18:27 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      2/24/23 4:38:02 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      10/3/22 4:15:29 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13D/A - LAVA Therapeutics NV (0001840748) (Subject)

      9/30/22 4:45:59 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by LAVA Therapeutics N.V. (Amendment)

      SC 13G/A - LAVA Therapeutics NV (0001840748) (Subject)

      2/14/22 5:07:16 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by LAVA Therapeutics N.V.

      SC 13D - LAVA Therapeutics NV (0001840748) (Subject)

      4/8/21 4:31:51 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by LAVA Therapeutics N.V.

      SC 13G - LAVA Therapeutics NV (0001840748) (Subject)

      4/8/21 4:11:16 PM ET
      $LVTX
      Biotechnology: Pharmaceutical Preparations
      Health Care